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Abstract The tumour suppressor LKB1 plays a critical
role in cell proliferation, polarity and energy metabolism.
LKB1 is a Ser/Thr protein kinase that is associated with
STRAD and MO25 in vivo. Here, we describe the individual
expression of the three components of the LKB1 complex
using monocistronic vectors and their co-expression using
tricistronic vectors that were constructed from monocistronic
vectors using a fully modular cloning approach. The data
show that among the three individually expressed compo-
nents of the LKB1 complex, only MO25a can be expressed
in soluble form, whereas the other two, LKB1 and STRADa
are found almost exclusively in inclusion bodies. However,
using the tricistronic vector system, functional LKB1-
MO25a-STRADa complex was expressed and purified from
soluble extracts by sequential immobilized-metal affinity and
heparin chromatography, as shown by Western blotting using
specific antibodies. In size exclusion chromatography,
MO25a and STRADa exactly co-elute with LKB1 with an
apparent molecular weight of the heterotrimeric complex of
160 kDa. The specific activity in the peak fraction of the size
exclusion chromatography was 250 U/mg at approximately
25% purity. As shown by autoradiography, LKB1 and
STRADa, both strongly autophosphorylate in vitro. More-
over, recombinant LKB1 complex activates AMPK by
phosphorylation of the a-subunit at the Thr-172 site as shown
(i) by Western blotting using phospho-specific antibodies
after LKB1-dependent phosphorylation, (ii) by LKB1-
dependent incorporation of radioactive phosphate into the
a-subunit of kinase dead AMPK heterotrimer, and (iii) by
activity determination of AMPK. Functional mammalian
LKB1 complex is constitutively active, and when enriched
from bacteria should prove to be a valuable tool for studying
its molecular function and regulation.
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Abbreviations
AMPK AMP-activated protein kinase
IMAC immobilized metal-ion affinity
chromatography
SAMS the synthetic peptide substrate of AMPK
corresponding to the sequence
HMRSAMSGLHLVKRR
SDS-PAGE sodium dodecylsulfate polyacrylamide gel
electrophoresis




CaMKK Ca2+/calmodulin-dependent protein kinase
kinase
GST glutathione-S-transferase
SAMS synthetic peptide HMRSAMSGLHLVKRR
MO25 mouse protein 25
SEC size exclusion chromatography
STRAD STE-20 related adaptor protein
Introduction
Mutations in the LKB1 (also called STK11) tumour sup-
pressor gene, which encodes a Ser/Thr protein kinase,
cause the Peutz–Jeghers cancer syndrome (PJS) [1, 2].
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Recent work identified LKB1 as a multitasking protein
kinase playing important roles in cell proliferation, polarity
and energy metabolism (reviewed in [3]). The cellular
localization and activity of LKB1 is likely controlled
through its interaction with a pseudokinase, termed
STRAD, and an armadillo repeat-containing protein,
named mouse protein 25 (MO25) [3]. Both, MO25 and
STRAD, occur in two different isoforms, a and b [4].
Genetic and biochemical findings indicate that LKB1
phosphorylates and thereby activates 14 protein kinases, all
related to the AMP-activated protein kinase (AMPK) [5, 6].
Much recent research has focused on the cellular role of
LKB1, but information about the kinase molecule itself is
still lacking, partly due to the limited availability of the
purified LKB1 protein complex. Bacterial expression of
fusion proteins corresponding to LKB1 with hexahistidine,
GST and MBP tags resulted either in insoluble aggregates
or heavily degraded protein that were found to be non-
functional [7]. We recently developed a polycistronic
expression strategy for co-expression of multiple proteins
in E. coli and, using this system, successfully produced
functional heterotrimeric AMPK [8, 9], a fuel sensor of the
cell and master regulator of energy metabolism [10].
AMPK is also a direct physiological target of LKB1 [11–
14]. Moreover, the LKB1 tumour suppressor function
might relate to inhibition of cell proliferation in response to
low-cellular energy levels by deregulation of AMPK that is
acting upstream of mTOR, the mammalian target of rapa-
mycin [15–17]. Here, we set out on establishing a bacterial
co-expression system for the functional LKB1 complex
consisting of LKB1, MO25a and STRADa.
Materials and methods
Construction of expression vectors
Modified pET-vectors were used as described previously [9].
Briefly, the cDNAs encoding LKB1, M025a and STRADa
(GenBank Accession No. NM_011492, BC020570,
AF308302) were subcloned by PCR and inserted into the
NdeI/SpeI sites of pET3ax (resulting in pLKB1, pMO25a
and pSTRADa) or in the NdeI/SpeI sites of pET14bx
(resulting in pHis-LKB1, pHis-MO25a and pHis-STRADa).
The following primers were utilized for subcloning: 5¢LKB1,
AAA AAA CAT ATG GAC GTG GCG GAC CCC G;
3¢LKB1, AAA AAA CTA GTT ACT GCT GCT TGC AGG
CCG AG; 5¢MO25a, AAA AAC ATA TGC CGT TCC CGT
TTG GGA AGT; 3¢MO25a, AAA AAC TAG TTA AGC TTC
TTG CTG AGC TGG TCT CTT; 5¢STRADa AAA AAC
ATA TGT CAT TTC TTG TAA GTA AAC CAG AGC GAA
TCA GG; 3¢STRADa, AAA AAC TAG TTA GAA CTC
CCA ATC GTC CAC CTC C (recognition sequences of NdeI
and SpeI underlined). Open reading frames of all constructs
were sequenced utilizing the BigDyeTM Terminator Cycle
Sequencing Kit (PE Applied Biosystems, Rotkreuz, Swit-
zerland) in an ABI Prism 310 Sequencer according to the
manufacturers instructions. The monocistronic vectors were
used for construction of the tricistronic expression vectors by
repetitive subcloning cycles as described in Fig. 1. Plasmid
constructs are listed in Table 1.
Expression and purification of LKB1, MO25a and
STRADa
Plasmids pHis-LKB1, pHis-MO25a and pHis-STRADa
encoding N-terminally hexahistidine-tagged LKB1,
MO25a and STRADa, respectively, were transformed into
competent host cells (E. coli BL21-StarTM(DE3), Invitro-
gen, Basel, Switzerland) and incubated overnight at 37C
on LB agar containing 150 lg/ml ampicillin. Resuspended
Fig. 1 Cloning scheme for construction of the tricistronic expression
vector. (A) The cDNA sequences encoding LKB1, MO25a and
STRADa were subcloned into individual pET-plasmids, harboring an
ampicillin resistance gene (ampR) and carrying an SpeI-site, which
results in the monocistronic vectors termed ‘pLKB1’, ‘pMO25a’ and
‘pSTRADa’. These vectors are suitable for bacterial expression of
individual proteins. Each of the monocistronic vectors may also
encode an N-terminal hexahistidine-tag (termed ‘pHis-LKB1’, ‘pHis-
MO25a’ and ‘pHis-STRADa’) to facilitate protein purification. (B)
Any of the monocistronic vectors can be used to accept XbaI/EcoRI
fragments harboring a functional cistron and encoding any of the
other proteins by restriction with SpeI/EcoRI and ligation. As XbaI
and SpeI sites are compatible but not recleavable by either of the
restriction enzymes, the introduction of a third cistron can follow the
same scheme. Successive restriction and ligation of individual
cistrons, encoding MO25a and STRADa, using the acceptor vector
pLKB1 leads to the final tricistronic vector (C) pLKB1MO25a
STRADa. (D) The tricistronic gene construct consists of a promoter,
ribosome binding sites (RBS), the open reading frames of LKB1,
MO25a and STRADa, as well as a transcriptional terminator. The
three restriction sites necessary for cloning are indicated and plasmid
names are underlined. Plasmid maps are not drawn to scale. The
cloning scheme is a variation of the method in Ref. [9] using EcoRI
instead of BlpI for uniqueness of the former site in all open reading
frames and vector sequence
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cells of each plate were used to inoculate 1 l auto-induction
medium ZYM-5052 as described by Studier [18]. Cultures
were grown in a shaker incubator at 37C and 350 rpm.
Cells were harvested after growth overnight, resuspended
in lysis buffer (50 mM Na-phosphate pH 8.0, 150 mM
NaCl, 10 mM imidazole, 1 mM b-mercaptoethanol) and
sonicated on ice in a Branson 250 sonifier (50% duty,
output 5, 2 min, 3 times). For purification of hexahistidine-
tagged MO25a insoluble material was removed by centri-
fugation and the supernatant was loaded onto Ni-NTA agarose
(Qiagen, Basel, Switzerland). The column was washed (three
column volumes with lysis buffer, containing 20 mM imid-
azole) and eluted (lysis buffer, containing 250 mM imidaz-
ole). For purification of hexahistidine-tagged LKB1 and
STRADa, the insoluble material was collected by centrifu-
gation after lysis and resuspended in lysis buffer containing
0.1% Triton X-100. After repetitive sonication, centrifugation
and resuspension (3 times), the pellet was collected by cen-
trifugation and solubilized in denaturing buffer containing
6 M guanidine hydrochloride (Gu-HCl), 20 mM imidazole
and 50 mM Na-phosphate, pH 8.0. After centrifugation, the
supernatant was loaded on a 5 ml Ni2+-charged HiTrap
Chelating HP column (GE Healthcare Europe, Otelfingen,
Switzerland), washed with 20 ml denaturing buffer and eluted
with denaturing buffer containing 250 mM imidazole. Pooled
elution fractions of each protein were stored at –20C until
usage. Prior to analysis by SDS-PAGE, 6 M Gu-HCl was
removed by dialysis against 8 M Urea.
Co-expression of LKB1, MO25a and STRADa: small
scale expressions
The tricistronic plasmids pLKB1MO25aSTRADa, pHis-
LKB1MO25aSTRADa, pLKB1His-MO25aSTRADa and
pLKB1MO25aHis-STRADa were transformed into com-
petent host cells (E. coli BL21-StarTM(DE3), Invitrogen,
Basel, Switzerland) and incubated overnight at 37C on LB
agar. For co-expression of bacterial chaperones competent
Tuner(DE3) cells, or Tuner(DE3) cells harboring either
pOFXT7-SL2 or pOFXT7-KJE2 [19], were transformed
with pHis-LKB1MO25aSTRADa. Appropriate antibiotics
were added at the following concentrations: 150 lg/ml
ampicillin and 25 lg/ml chloramphenicol. Resuspended
cells of each plate were used to inoculate 1 l auto-induction
medium ZYM-5052 as described by Studier [18], cells
were collected and lysed by sonication. Soluble fractions
were analyzed by SDS-PAGE and Coomassie Blue-stain-
ing or Western-blotting followed by immuno-detection as
described below.
Co-expression of LKB1, MO25a and STRADa and
purification of the complex
The tricistronic plasmid pHis-LKB1MO25aSTRADa was
transformed into competent host cells (E. coli BL21-
StarTM(DE3), Invitrogen, Basel, Switzerland) and incu-
bated overnight at 37C on LB agar containing 150 lg/ml
ampicillin. Resuspended cells were used for inoculation of
800 ml M9* medium (25.5 g/l Na2HPO4*2H2O, 9 g/l
KH2PO4, 1 g/l NH4Cl, 0.5 g/l NaCl, 2 mM MgSO4, 0.5%
w/v glucose, 2 ml/l TE and 150 mg/l ampicillin) and agi-
tated in shaker flasks at 37C at 250 rpm. After 24 h
growth the cells were used for inoculation of a 42 l bio-
reactor (MBR Switzerland 1982) containing 27 l Riesen-
berg medium (13.3 g/l KH2PO4, 4.0 g/l (NH4)2HPO4,
1.7 g/l citric acid, 1.5 ml polypropylene glycol 2000 as
antifoam, supplemented with 2 ml/l 2M MgSO4, and
Table 1 Overview of plasmids used throughout this study
Plasmid Insert/Modification
pET3ax Introduction of SpeI site to pET3a
pET14bx Introduction of SpeI site to pET14b
pLKB1 LKB1 subcloned into the NdeI/SpeI sites of pET3ax
pMO25a MO25a subcloned into the NdeI/SpeI sites of pET3ax
PSTRADa STRADa subcloned into the NdeI/SpeI sites of pET3ax
pHis-LKB1 LKB1 subcloned into the NdeI/SpeI sites of pET14bx
pHis-MO25a MO25a subcloned into the NdeI/SpeI sites of pET14bx
pHis-STRADa STRADa subcloned into the NdeI/SpeI sites of pET14bx
pLKB1MO25a pLKB1 digested with SpeI/EcoRI and ligated to XbaI/EcoRI-fragment of pMO25a
pHis-LKB1MO25a pHis-LKB1 digested with SpeI/EcoRI and ligated to XbaI/EcoRI-fragment of pMO25a
pLKB1His-MO25a pLKB1 digested with SpeI/EcoRI and ligated to XbaI/EcoRI-fragment of pHis-MO25a
pLKB1MO25aSTRADa pLKB1MO25a digested with SpeI/EcoRI and ligated to XbaI/EcoRI-fragment of pSTRADa
pHis-LKB1MO25aSTRADa pHis-LKB1MO25a digested with SpeI/EcoRI and ligated toXbaI/EcoRI-fragment of pSTRADa
pLKB1His-MO25aSTRADa pLKB1His-MO25a digested with SpeI/EcoRI and ligated toXbaI/EcoRI-fragment of pSTRADa
pLKB1MO25aHis-STRADa pLKB1MO25a digested with SpeI/EcoRI and ligated to XbaI/EcoRI-fragment of pHis-STRADa
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150 mg/l ampicillin) with 1.7% (w/v) glucose. Titration
with 35% NH4OH and 30% H3PO4 was used to keep pH
constant at 7.2. Trace element solution (TE) containing
1 M HCl, 7.6 mM MnCl2, 3.6 mM ZnSO4, 4.8 mM
H3BO3, 1.2 mM Na2MoO4, 0.9 mM CoCl2, 2.26 mM
Na2EDTA, 37.1 mM CaCl2, 15.9 mM FeSO4, 10 mM
CoSO4, 2 mM H2SeO3, was added to final amount of 2 ml/
l culture. Cells were batch grown for 12 h at 34C until
depletion of glucose and acetate (pO2 ~ 100%). After start
of 65% (w/v) glucose feed, TE solution and 2 ml/l 2 M
MgSO4 were added. The feed was balanced with O2 con-
sumption until onset of pO2 limitation at a mass flow air of
45 l/min with overpressure of 0.5 bar and at stirrer maxi-
mum of 1000 rpm. Further TE solution and 1 ml/l 2 M
MgSO4 were added each 15–20 OD600nm’s and after
induction each 2.5 h. Growth temperature was reduced to
27C and cells were induced with 50 mg/l IPTG at
OD600nm = 36 for 7 h. Cells were harvested by centrifu-
gation, washed in 0.9% (w/v) NaCl solution and centri-
fuged again. The final cell pellet was frozen in liquid
nitrogen and stored at –20C until usage. A bacterial cell
pellet corresponding to 100 g wet weight was resuspended
in ice-cold lysis buffer (15% sucrose w/v, 50 mM Na-
phosphate pH 8.0, 30% (w/v) glycerol, 10 mM imidazole,
1 mM b-mercaptoethanol). Cells were lysed in a high-
pressure homogenizer (EmulsiFlex-C5, Avestin, Canada)
at 1000 bar. Insoluble material was removed by centrifu-
gation and the supernatant was loaded onto Ni-NTA aga-
rose (Qiagen, Basel, Switzerland). The column was washed
with three column volumes of lysis buffer, containing
20 mM imidazole and eluted with lysis buffer, containing
250 mM imidazole. Pooled Ni-NTA elution fractions were
diluted 20-fold with heparin loading buffer (100 mM NaCl,
10 mM Tris-Cl, pH 7.2) and loaded onto a 1 ml HiTrap
Heparin column (GE Healthcare Europe, Otelfingen, Swit-
zerland). Protein was eluted with heparin elution buffer (1M
NaCl, Tris-Cl, pH 7.2) and elution fractions were stored
at 4C until further analysis. Snap freezing in liquid nitrogen
is possible without significant loss of kinase activity, but
repeated freeze and thaw cycles are not recommended.
Size exclusion chromatography
A heparin elution fraction containing LKB1 complex was
subjected to size exclusion chromatography (SEC). About
1.2 mg of partly purified LKB1 complex were separated in
250 mM NaCl, 2 mM MgCl2, 1 mM dithiothreitol and
10 mM Tris-Cl, pH 7.2 at a flow rate of 0.5 ml min–1 and a
temperature of 7C with a Superose 12 HR 10/30 column
connected directly between the UV/VIS flow cell and the
injection valve of an A¨kta Explorer 100 Air HPLC system
(GE Healthcare Europe, Otelfingen, Switzerland). The
column was calibrated for molecular weight with the
following marker proteins (GE Healthcare Europe, Otelf-
ingen, Switzerland): carbonic anhydrase (29 kDa), bovine
serum albumin (67 kDa), alcohol dehydrogenase
(150 kDa), b-amylase (200 kDa), apoferritin (443 kDa)
and thyroglobulin (669 kDa).
SDS-PAGE and Western blotting
Protein samples were diluted in Laemmli SDS sample
buffer and snap frozen in liquid nitrogen at indicated time
points. After SDS-PAGE (12% polyacrylamide) and
transfer to Protran BA85 nitrocellulose membranes
(Whatman, Bottmingen, Switzerland), the membranes were
blocked in TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl)
with 5% low-fat milk powder or bovine serum albumin.
The antibodies were applied in the same buffer at various
dilutions and the blots were incubated for 2–16 h. After
extensive washing in TBS, blots were incubated for 1 h at
room temperature with horseradish peroxidase-coupled
secondary antibodies. After repeated extensive washing,
signals were detected with enhanced chemiluminescence
(Applichem, Axon Lab, Baden-Da¨ttwil, Switzerland) and
Kodak X-ray-sensitive films (Kodak SA, Renens, Swit-
zerland). The following primary and secondary antibodies
were used at appropriate dilution: goat anti-LKB1 (Santa
Cruz, Cat. No. sc-5637), sheep anti-MO25a and anti-
STRADa were purchased from Dr. Alessi, Dundee, mouse
Penta-His antibody (Qiagen, Cat No. 34660), rabbit anti-
AMPKc was a kind gift of Dr. David Carling, phospho-
specific AMPKa Thr-172 monoclonal antibodies (Cell
Signaling Technology, BioConcept, Allschwil, Switzer-
land), goat anti-mouse peroxidase conjugated (Pierce,
Perbio Science, Lausanne, Switzerland), goat anti-rabbit
peroxidase conjugated (Calbiochem, VWR, Dietikon,
Switzerland), and mouse anti-goat/sheep peroxidase con-
jugated (Sigma/Fluka, Buchs, Switzerland).
Kinase activity determination
Protein fractions containing recombinant LKB1 complex
were assayed using LKBtide (an artificial peptide substrate
corresponding to the sequence LSNLYHQGKFLQTFCG
SPLYRRR) and non-radioactive ATP. The buffer for
LKB1 activity determination consisted of 100 mM HEPES,
pH 7.1, 1 mM DTT, 5 mM MgCl2, 1 mM ATP, 250 lM
LKBtide. LKB1 activity assays were performed in
Eppendorf tubes on a thermal shaker at 30C and 300 rpm.
After incubation (10 or 20 min) the assay mixture was snap
frozen in liquid nitrogen and stored at –20C until further
analysis. The amount of non-phosphorylated and phos-
phorylated LKBtide was quantified by HPLC analysis,
analogous to AMPK activity determination as reported
previously [20]. Briefly, a cation exchange column (Source
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15S, 1 ml, from GE Healthcare Europe, Otelfingen, Swit-
zerland) in a HPLC-system equipped with two independent
UV/VIS spectrometers (Shimadzu, Reinach, Switzerland)
was used for separation and quantitation of peptides.
Samples were eluted with a linear gradient (0–0.5 M NaCl
in 5 mM Na-phosphate, pH 3.0 containing 15% acetoni-
trile). and monitored at 280 and 220 nm. The latter
wavelength was used for quantitation, because absorbance
of peptide bonds at 220 nm is much stronger than that of
aromatic amino acids at 280 nm. LKB1 activities were
calculated from HPLC chromatograms by integration of
the peak corresponding to phosphorylated LKBtide.
AMPK-activity was assessed with SAMS-peptide as sub-
strate as described recently [20].
Expression and purification of AMPK
Wild-type AMPK a1b1c1, a2b2c1, and kinase-defective
mutant AMPK a1D157Ab1c1 were bacterially expressed
and purified on Ni-NTA superflow columns (Qiagen, Basel,
Switzerland) following the procedure described in Ref. [9].
AMPK was further processed to highest purity and stock
solutions of the enzyme were kept in 50% glycerol at –20C.
Phosphorylation of AMPK by LKB1
Autophosphorylation of LKB1 complex (using the heparin
elution peak fraction) was performed for 30 min at 30C in
assay buffer containing 200 lM ATP, 50 lM AMP, 5 mM
MgCl2, 1 mM DTT and 10 mM HEPES, pH 7.4. The
reaction volume was doubled using assay buffer supple-
mented with c32P-ATP (specific activity of 1.35 mCi/ml)
and 500 ng of AMPK. After incubation for 10 min at 37C,
the reactions were stopped by addition of Laemmli SDS
sample buffer and immediate heating at 95C for 5 min.
Aliquots of 400 ng AMPK were subjected to SDS-PAGE
and autoradiography. Briefly, Coomassie-stained gels were
dried on 3MM Chr paper (Whatman, Bottmingen, Swit-
zerland) and exposed to BioMax MR films (Kodak SA,
Renens, Switzerland) at –80C for 14 h. The residual
100 ng of AMPK were separated by SDS-PAGE and
Western-blotting was performed as described above.
Results
Expression of LKB1, MO25a and STRADa in E. coli
In this study, a bacterial co-expression strategy was at-
tempted to yield functional LKB1-MO25a-STRADa pro-
tein complex. The cloning procedure for construction of a
tricistronic gene starts by construction of monocistronic
expression vectors (Fig. 1). Individual plasmids encoding
for either hexahistidine-tagged LKB1, MO25a or STRA-
Da were used first to produce these proteins separately in
E. coli. After expression, lysis and centrifugation, soluble
and insoluble fractions of the respective individual pro-
teins were analyzed by SDS-PAGE and Western-blotting
using antibodies recognizing the hexahistidine-tag
(Fig. 2). The results show that most of the MO25a protein
was found in the soluble fraction, whereas only a very
small fraction of LKB1, and even partly degraded, was
found in the soluble extract, and no soluble STRADa was
detectable at all (Fig. 2B, lanes 1–3). Thus, immobilized
metal-ion affinity chromatography (IMAC) was used to
purify MO25a from soluble extracts, whereas LKB1 and
STRADa were solubilized from inclusion bodies prior to
purification under denaturing conditions. Eluates were
analyzed by SDS-PAGE and Western blotting (Fig. 3).
The Coomassie Blue-stained gel reveals high purity of the
individual proteins after single step purification (Fig. 3A).
The theoretical molecular weights of MO25a (39.9 kDa)
and STRADa (48.4 kDa) correspond well to the estimated
apparent molecular weights of 40 and 50 kDa, respec-
tively (Fig. 3, lanes 2 and 3). In accordance with an
earlier report [7], the observed apparent molecular weight
of LKB1 in SDS-PAGE is around 60 kDa (Fig. 3A, lane
1), which is higher than the expected 49.3 kDa even if
taking into account the hexahistidine-tag (51.4 kDa).
Specific antibodies raised either against LKB1, MO25a or
STRADa clearly show immunoreactivity against their
corresponding immunogens (Fig. 3B–D) at the molecular
weight of the protein bands as seen in the Coomassie
Blue-stained gel (Fig. 3A). Western-blots of hexahisti-
dine-tagged LKB1 and STRADa that were purified from
inclusion bodies both show additional signals with higher
electrophoretic mobility in SDS-PAGE indicating possible
degradation products. As these peptides were immuno-
reactive with antibodies recognizing the N-terminal
hexahistidine-tag (Fig. 3E), they are likely due to C-ter-
minal truncations. Expectedly, the antibodies that recog-
nize the hexahistidine-tag show a signal for LKB1,
MO25a and STRADa at the same position on the Wes-
tern-blot that was recognized by the protein-specific
antibody (compare Fig. 3B–D with E). Taken together,
hexahistidine-tagged LKB1, MO25a and STRADa have
been bacterially expressed and purified by single step
IMAC, and the corresponding antibodies specifically
recognize their immunogens on Western-blots. Our data
show that from the three individually expressed compo-
nents of the LKB1 complex, only MO25a can be obtained
in soluble form in significant quantities, whereas the other
two, LKB1 and STRADa, are found preferentially in the
insoluble fraction.
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Co-expression of LKB1, MO25a and STRADa:
Positional effect of hexahistidine-tag
A series of tricistronic plasmids encoding for all three
subunits of the LKB1 complex, with either none or a single
subunit hexahistidine-tagged (pLKB1MO25aSTRADa,
pHis-LKB1MO25aSTRADa, pLKB1His-MO25a
STRADa, pLKB1MO25aHis-STRADa), were constructed
following the cloning scheme shown in Fig. 1. After
transformation of such tricistronic plasmids into bacteria
and overnight growth in auto-inducing media [18], the
expression levels of all subunits in soluble extracts were
evaluated by Western-blotting after SDS-PAGE (Fig. 4).
Despite co-expression of all three subunits of the LKB1
complex, LKB1 and STRADa were not detectable in the
supernatant with available protein specific antibodies di-
rected against LKB1 and STRADa (data not shown).
However, if fused to the hexahistidine-tag and using the
tag-specific antibody, some faint signal was apparent for
LKB1 and STRADa (Fig. 4B, lanes 2 and 1, respectively),
suggesting low abundance of the corresponding proteins in
the soluble bacterial extract. In contrast, MO25a gave a
strong signal if using the tag-specific antibody (Fig. 4B,
lane 3). Moreover, a strong band corresponding to MO25a
appeared in all soluble extracts after SDS-PAGE analysis
in Coomassie-Blue stained gels (Fig. 4A, lane 1–4), which
is consistent with soluble expression of MO25a in absence
of LKB1 and STRADa (Fig. 2). Importantly, no significant
differences between results from different tricistronic
constructs were observed, suggesting that the affinity-tag
did not affect soluble expression of either subunit.
Co-expression of LKB1, MO25a and STRADa with
chaperones
We have chosen to utilize the tricistronic vector encoding
non-tagged MO25a and STRADa, and hexahistidine-tag-
ged LKB1 (pHis-LKB1MO25aSTRADa) for further stud-
ies and analyzed, whether co-expression of bacterial
chaperones would result in enhanced solubility of LKB1 by
Western-blotting (Fig. 5). Co-expression of DnaK/DnaJ/
GrpE increased soluble expression of full-length LKB1
Fig. 2 Solubility analysis of LKB1, MO25a and STRADa after
expression from individual monocistronic vectors. Plasmids encoding
hexahistidine-tagged LKB1 (lanes 1), MO25a (lanes 2) or STRADa
(lanes 3), were transformed to competent E. coli and harvested after
overnight expression in auto-inducing media. After lysis the total,
soluble and insoluble bacterial extracts were analyzed by SDS-PAGE.
(A) Coomassie Blue stained gel. (B) Immuno-detection of proteins
after Western-blotting using antibodies recognizing the hexahistidine-
tag
Fig. 3 Purification of separate LKB1, MO25a or STRADa proteins
and evaluation of antibodies. Hexahistidine-tagged LKB1, MO25a
and STRADa were expressed individually in bacteria using the
monocistronic vectors pHis-LKB1, pHis-MO25a and pHis-STRADa,
respectively. LKB1 and STRADa accumulated in inclusion bodies
and were purified under denaturing conditions by IMAC, whereas
MO25a was partly soluble and was purified from soluble extracts by
IMAC (not shown). Purified proteins were analyzed by SDS-PAGE
followed by Coomassie-Blue staining (A) or Western-blotting (B-E).
Separate Western-blots were prepared for probing with four different
antibodies as indicated. Lane 1, LKB1; lane 2, MO25a; lane 3,
STRADa; lane 4: LKB1, MO25a and STRADa (1 lg each)
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(Fig. 5B, lane 1 vs. 2), whereas GroES/GroEL reduced the
expression level of the full-length protein (Fig. 5B, lane 1
vs. 3). Apparently, co-expression of either chaperone sys-
tems also resulted in a number of strong signals at lower
molecular weight, likely due to increased proteolysis of
LKB1 (Fig. 5B, lanes 2, 3), which are, however, almost
absent when the tricistron is expressed without assistance
of chaperones (Fig. 5B, lane 1). Therefore, expression of
LKB1 complex was pursued without co-expression of
bacterial chaperones.
Co-expression of LKB1, MO25a and STRADa:
Purification of the complex
Expression utilizing the tricistronic constructs (Figs. 4 and
5) showed that all three proteins appeared in soluble ex-
tracts at least if hexahistidine-tagged, although expression
levels of soluble LKB1 and STRADa were much lower in
comparison to MO25a. Thus, we have chosen to express
the tricistronic plasmid encoding hexahistidine-tagged
LKB1 at larger scale and to purify proteins chromato-
graphically to explore whether a stable complex between
LKB1, MO25a and STRADa may have formed. As ex-
pected from previous results, no obvious protein bands
appeared in the soluble extract at the expected molecular
weight of LKB1, as judged from visual inspection of
Coomassie Blue-stained gels after SDS-PAGE (Fig. 6A,
lane 1). Neither IMAC did result in highly enriched
hexahistidine-tagged LKB1 (Fig. 6A, lane 2), although the
tag-specific antibody recognized LKB1 protein at the ex-
pected molecular weight in IMAC eluates, giving a
somewhat stronger signal than in soluble extracts (Fig. 6E,
lanes 1 and 2). For second-step purification, different ion-
exchange matrices were tested, however, heparin at slightly
basic conditions was found most effective (data not
shown). After IMAC and heparin chromatography LKB1,
MO25a and STRADa were highly enriched as shown by
Western-blotting (Fig. 6B–E, lane 3). Still several other
protein bands appeared in the eluate (Fig. 6A, lane 3). The
unexpected signal at around 70 kDa, which is significantly
higher than the molecular weight of STRADa (Fig. 6D,
lanes 1 and 2), disappeared after heparin chromatography
(Fig. 6D, lane 3) indicating some unspecificity of the
STRADa antibody. The presence of MO25a in all fractions
(Fig. 6A, lanes 1–3) may only reflect the comparatively
higher solubility of MO25a, which is in excess to LKB1
and STRADa in soluble extracts and is rather purified away
in later steps, reaching roughly equimolar levels with
LKB1 and STRADa after heparin chromatography (Fig. 6,
compare signal intensities in lanes 3 and 4 of B, C, D, E, if
considering loading of lane 4 is 1 lg each). Kinase activity
of LKB1 can be determined by incorporation of 32P-
phosphate into a synthetic peptide substrate of LKB1,
LKBtide [21]. A recent study in our lab utilized an HPLC-
based detection method to separate and quantify non-
phosphorylated and phosphorylated peptides for activity
determination [20]. Here, we modified this method to allow
for LKB1 activity measurements using LKBtide. A repre-
sentative analysis of samples taken at different time points
from an LKB1 activity assay is shown in Fig. 7. The
enzymatic activities of LKB1 were quantified for each
purification step and data are summarized in Table 2. The
large proportion of the total LKB1 activity was lost during
IMAC and heparin chromatography, as reflected by the low
overall yield (5.1%). Nevertheless, in two subsequent
purification steps the specific activity increased from 2.3 to
100 U/mg. Most importantly, LKB1 was active in crude
bacterial extracts as well as in all elution fractions, sug-
gesting that LKB1 is constitutively active in vitro. In our
expression and purification scheme only hexahistidine-
tagged LKB1 is expected to specifically bind to the IMAC-
column and heparin is unlikely to bind LKB1, MO25a and
STRADa with equal affinity. Thus, co-elution of all three
subunits, as shown by Western-blotting after two chro-
matographic steps, already indicates the formation of a
stable protein complex between the three subunits (Fig. 6,
lanes 3B–E).
Size exclusion chromatography of LKB1 complex
Partly purified, recombinant LKB1 complex corresponding
to 120 Units (1.2 mg of the heparin peak elution) was
Fig. 4 Positional effect of hexahistidine-tag on expression of LKB1,
MO25a or STRADa from tricistronic vectors. The plasmids
pLKB1His-STRADaMO25a (lanes 1), pHis-LKB1STRADaMO25a
(lanes 2) or pLKB1STRADaHis-MO25a (lanes 3), pLKB1STRA-
DaMO25a (lanes 4), were transformed to competent E. coli and
harvested after overnight expression in auto-inducing media. After
lysis and centrifugation the soluble bacterial extracts were analyzed
by SDS-PAGE. (A) Coomassie Blue stained gel. The strong visible
band at 40 kDa corresponds to MO25a, the shift in lane 3 is due to the
N-terminally fused hexahistidine-tag. (B) Immuno-detection of
hexahistidine-tagged proteins after Western-blotting using antibodies
raised against the tag. The very strong signal (lane 3) corresponds to
MO25a, whereas LKB1 (lane 2) and STRADa (lane 1) give only
weak signals. The control (lane C) is the same as in Fig. 3, lane 4
(hexahistidine-tagged LKB1, MO25a and STRADa, 1 lg each
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subjected to size exclusion chromatography (SEC) and
fractions were collected for further analysis by SDS-
PAGE, Western-blotting and activity determination
(Fig. 8). The UV-trace of the chromatogram shows three
major peaks (Fig. 4A, thick solid line). LKB1 activity
eluted between ADH (MW 150 kDa) and b-amylase (MW
200 kDa) marker proteins as a single peak (Fig. 8, broken
line), which co-localizes with the first major peak of the
UV-trace in the chromatogram. Based on the calibration
data (Fig. 8, regression line) this peak corresponds to an
apparent molecular weight of 160 kDa. Maximal specific
activity in the peak fraction was 250 U/mg (Fig. 8A,
fraction 9, marked by an asterisk). Thus, the overall
efficiency of the purification strategy is more than 100-fold
and is showing a steady increase of specific activities
(Fig. 9), and LKB1 activities subjected to SEC were
recovered completely (data not shown). LKB1, MO25a and
STRADa exactly co-eluted from the column as shown by
Western-blotting using specific antibodies (Fig. 8B).
Moreover, the fractions exhibiting the highest specific
activities also show highest signal intensities for LKB1,
MO25a and STRADa (Fig. 8B), again indicating the for-
mation of a stable LKB1-MO25a-STRADa complex.
Inspection of the Coomassie Blue-stained gel after sepa-
ration of the SEC column fractions also reveals visible
staining at the expected molecular weight of LKB1,
MO25a and STRADa. These protein bands coincide and
co-localize with the Western-blot signals, suggesting that
all three proteins have reached detectable levels with this
staining method. Based on correct identification of the
protein bands, densitometric analysis indicates that the
overall purity of LKB1-MO25a-STRADa complex in
fraction 9 is approx. 25%.
Fig. 5 Co-expression of bacterial chaperones with a tricistronic
vector encoding hexahistidine-tagged LKB1, and non-tagged MO25a
and STRADa. The tricistronic plasmid (pHis-LKB1MO25aSTRADa)
was transformed to three different competent E. coli cells, without co-
expression of chaperones (lane1), or harbouring pOFXT7-KJE2 for
co-expression of DnaJ/DnaK/GrpE (lane 2) or pOFXT7-SL2 for co-
expression of GroES/GroEL (lane 3). Cells were harvested after
overnight expression in auto-inducing media and lysed by sonication.
Soluble bacterial extracts were analyzed by SDS-PAGE. (A)
Coomassie Blue stained gel. No major differences are seen between
samples. (B) Immuno-detection of hexahistidine-tagged proteins after
Western-blotting. Only LKB1 is fused to the tag and signals
corresponding to full-length LKB1 are visible in all lanes to varying
degrees. However, additional signals at lower molecular weight
appear in samples after co-expression of both bacterial chaperone
systems (lanes 2 and 3)
Fig. 6 Purification of LKB1 complex. Cells were lysed and
centrifuged after bacterial co-expression of untagged MO25a,
STRADa and hexahistidine-tagged LKB1, using the tricistronic
expression vector pHis-LKB1MO25aSTRADa. The supernatant
representing the soluble extract was subjected to sequential IMAC
and heparin chromatography. Soluble extract, IMAC eluate, Heparin
eluate and control proteins were analyzed by SDS-PAGE followed by
Coomassie-Blue staining (A) or Western-blotting (B-E). Separate
Western-blots were prepared for probing with four different antibodies
as indicated. Lane 1, soluble extract (20 lg); lane 2, IMAC eluate
(20 lg); lane 3, heparin eluate (20 lg); lane 4: LKB1, MO25a and
STRADa (1 lg each, the same sample as in Fig. 3, lane 4)
Fig. 7 LKB1 activity determination. Aliquots of an LKB1 activity
assay were taken at different time points as indicated and subjected to
ion exchange chromatography using HPLC. The elution profiles show
time-dependent increase of phosphorylated LKBtide (LKBtide-P) and
concomitant decrease of the non-phosphorylated peptide (LKBtide)
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LKB1 complex phosphorylates and activates AMPK
A physiological target of LKB1 was recently identified as
AMP-activated protein kinase (AMPK) [11–13]. We used
recombinant AMPK that is almost entirely inactive to
verify the ability of LKB1 complex to activate AMPK by
phosphorylation at Thr-172 of the catalytic a-subunit.
Incorporation of radioactivity into the a- and b- subunits of
AMPK in presence, but not in absence of LKB1 complex
indicates phosphorylation of AMPK by LKB1 (Fig. 10B,
lanes 3, 5). Kinase-defective mutant AMPK a1-complex
incorporates radioactivity only into the catalytic AMPK a-
subunit, showing that LKB1 is phosphorylating exclusively
the a-subunit (Fig. 10B, lane 7). The absence of b-subunit
phosphorylation in kinase dead AMPK after incubation
with LKB1 is reflecting the inability of the AMPK mutant
to autophosphorylate after activation. Finally, Western-
blotting using antibodies recognizing phosphorylated
AMPK a Thr-172 (Fig. 10C) and activity determination
(Fig. 10D) confirms phosphorylation at Thr-172 that is a
pre-requisite of significant AMPK activity [20].
Discussion
LKB1 is known to interact with MO25 and STRAD in vivo
[4, 21]. Here, we show that the components of the LKB1
complex can be individually expressed, but with the
exception of MO25a, both LKB1 and STRADa are found
insoluble in inclusion bodies. Since subunits of protein
complexes often require their natural binding partners for
correct folding and solubility [22], we attempted co-
expression of all three proteins in bacteria, which turned
out to be a useful strategy for isolation of the functional
LKB1 complex from soluble extracts. The three polypep-
tides were identified as LKB1, MO25a and STRADa by
their apparent molecular weight, as determined by SDS-
PAGE and their reactivity with specific antibodies. MO25a
and STRADa co-eluted with hexahistidine-tagged LKB1
from the immobilized metal-ion affinity (IMAC) and hep-
arin columns. In size exclusion chromatography (SEC), the
highest LKB1 activities eluted at an apparent molecular
weight of 160 kDa (Fig. 8A), which is consistent with
complex-formation. Moreover, MO25a and STRADa
exactly co-eluted with LKB1 from the size exclusion col-
umn as shown by Western-blotting (Fig. 8B). Thus, we
presume that the LKB1, MO25a(and STRADa proteins
assemble into a 1:1:1 heterotrimeric complex in the cyto-
plasm of E. coli. Additionally, we show that recombinant
Table 2 Summary of purification of recombinant LKB1-MO25a-STRADa
Fraction Total activity (U)a Total protein (mg) Specific activity (U/mg) Purification (fold) Yield (%)
Lysate 19320 8400 2.3 1 100
IMAC 3386 102 33.2 14.4 17.5
Heparin 986 9.8 100.7 43.8 5.1
a One Unit is defined as 1 nmole phosphate incorporated into LKBtide per minute
Fig. 8 Size exclusion chromatography of partly purified LKB1
complex. 120 U (1.2 mg of the heparin elution peak fraction) were
separated on a Superose-12 HR 10/30 column. (A) The UV-trace
(thick solid line) gives the absorption at 280 nm (left scale). Elution
fractions (0.5 ml each) were collected and analyzed for LKB1 activity
(filled circles with broken line, inner right axis). The column was
calibrated for molecular weight by different marker proteins (triangles
with regression line, outer right axis). The highest specific activity of
250 U/mg elutes in fraction 9 (marked by an asterisk) at an apparent
molecular weight of 160 kDa. (B) Elution fractions of the size
exclusion column were further analyzed by SDS-PAGE and Western-
blotting using antibodies as indicated. Hexahistidine-tagged LKB1,
MO25a and STRADa proteins co-elute and the strongest signal
intensities are observed in elution fractions exhibiting the highest
LKB1 activities as shown in (A). Coomassie Blue-stained protein
bands that likely represent LKB1, STRADa and MO25a are framed
(top to bottom)
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LKB1 complex is capable of phosphorylating AMPK at
Thr-172 of the a-subunit, as was reported for the native
enzyme previously [13], and this phosphorylation also
leads to strongly increased activity of AMPK. We therefore
conclude that recombinant LKB1-MO25a-STRADa is
fully functional. In contrast to AMPK purified from bac-
teria, which is inactive unless activated by either of its
upstream kinases [9], the recombinant LKB1 complex is
highly active and strongly autophosphorylates after
extraction. Importantly, neither activation by upstream
kinases, nor other posttranslational modifications, like C-
terminal farnesylation of LKB1 [23], that may either not be
performed at all or only incorrectly by E. coli, were critical
for enzyme activity or stability of the complex, supporting
the notion that LKB1 is constitutively active in vitro. Such
constitutive activity of the LKB1 complex in vivo has been
recently suggested [3], but not experimentally proven.
Using tricistronic vectors, we explored the positional
effect of the N-terminal hexahistidine-tag on soluble
expression of the LKB1 complex. Soluble expression of
LKB1 and STRADa proteins could only be assessed if the
corresponding protein was hexahistidine-tagged and using
antibodies recognizing the tag, which revealed low but
comparable signal intensities for full-length tagged LKB1
and tagged STRADa. Hence, if present at all, positional
Fig. 10 Autophosphorylation LKB1-MO25a-STRADa and activa-
tion of AMPK. (A) Coomassie Blue-stained gel. (B) LKB1 and
STRADa strongly autophosphorylate, as shown by autoradiography
after incubation with radioactive ATP (lane 8), but pre-incubation of
LKB1 complex with non-radioactive ATP (lane 1–7) suppresses
signals derived from such autophosphorylation. No radioactivity is
incorporated in AMPK in absence of LKB1 (lanes 2, 4, 6), but clear
signals appear if LKB1 is allowed to phosphorylate AMPK (lanes 3,
5, 7). In wild-type AMPK the b-subunits are labelled in addition to a-
subunits (lanes 3, 5), but in kinase-defective mutant AMPK (D157A,
Asp-157 replaced with Ala), which is unable to autophosphorylate,
only the a-subunit is incorporating radioactivity (lane 7). (C) Western
blot of the same samples as in (A) using a phospho-specific Thr-172
antibody, showing that AMPK is phosphorylated by LKB1 complex
at this activating site (lanes 3, 5, 7). The c-subunit signals are
comparable in lanes 2–7 showing equal loading of AMPK. (D)
Activity determination of two different AMPK isoforms (a1b1c1 and
a2b2c1) before and after addition of upstream kinases (CaMKKb or
LKB1). Results are mean S.D. (n = 3)
Fig. 9 Specific activities of LKB1 in different elution fractions. Each
bar represents activity values that were calculated from a chromato-
gram (area under the curve) of a single HPLC run as shown in Fig. 7
Mol Biotechnol (2007) 36:220–231 229
effects are rather small and not detectable using the
methods applied here. We also addressed whether co-
expression of chaperones would augment soluble expres-
sion of LKB1-MO25a-STRADa and essentially found in-
creased signal intensities corresponding to lower molecular
weight products of LKB1, strongly suggesting enhanced
degradation rather than chaperone-assisted folding and
assembly of the complex, which is consistent with the
cellular roles of molecular chaperones and proteases for de
novo folding and quality control of proteins [24].
Densitometric analysis revealed an approximate purity of
25% for the LKB1-MO25a-STRADa complex in the LKB1
peak elution fraction after SEC (Fig. 8B, fraction 9, boxed
areas). The same SEC fraction also exhibited the maximal
specific activity of 250 U/mg, suggesting that homogeneous
LKB1 complex would exhibit around 1000 U/mg. The
specific activities of bacterially expressed LKB1 complex
are, however, difficult to compare with previous prepara-
tions from rat liver [25] that appeared to contain LKB1 [11],
but were reported prior to the development of LKBtide [5].
Co-expression of GST-fusions of LKB1, MO25a and
STRADa in HEK293 cells and affinity purification results in
significantly lower specific activities around 20 U/mg [21],
but the purity of these preparations remains elusive.
In this study, we also developed a new method for
quantitation of LKB1 activity from kinase assays using the
synthetic peptide substrate, LKBtide [5]. We determined
the amount of phosphorylated LKBtide by HPLC analysis
using non-radioactive ATP, thereby avoiding the use of
radioactivity and scintillation counting. In our opinion, the
HPLC method is very reliable and accurate, which justifies
its use in this and future studies, even though the traditional
radioactive method is less time consuming and many
activity determinations can be performed in parallel.
Co-expression of proteins in bacteria has recently gained
significant interest since rather assemblies of proteins than
single macromolecules form the functional units of the
eukaryotic cell, and one major challenge of the post-geno-
mic era is to produce these complexes in sufficient amounts
to be studied by biochemical and structural means [22]. It
should be emphasized that the virtual absence of the com-
mon eukaryotic posttranslational modifications in bacteria,
especially phosphorylation by endogenous kinases, consti-
tutes a major advantage of bacterial over-expression.
Undoubtedly, such wanted or unwanted posttranslational
modifications frequently occur after over-expression in
yeast, insect or mammalian cell based expression systems,
with the clear disadvantage that assignment of a biological
function to a certain modification can be obscured. Thus, the
LKB1 complex from bacteria offers a unique perspective of
studying the effect of posttranslational modifications on the
molecular level and provides a versatile reagent for bio-
chemical experimentation.
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